{"id":31412,"date":"2025-04-08T17:38:56","date_gmt":"2025-04-08T09:38:56","guid":{"rendered":"https:\/\/flcube.com\/?p=31412"},"modified":"2025-04-08T17:38:57","modified_gmt":"2025-04-08T09:38:57","slug":"amgens-uplizna-approved-by-fda-for-igg4-related-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31412","title":{"rendered":"Amgen’s Uplizna Approved by FDA for IgG4-Related Disease"},"content":{"rendered":"\n

US biotech giant Amgen (NASDAQ: AMGN<\/a>) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).<\/p>\n\n\n\n

Drug Profile and Mechanism<\/strong>
Uplizna is a CD19-targeted monoclonal antibody designed to address the underlying pathology of IgG4-RD, a rare and chronic autoimmune disorder. By binding to CD19, Uplizna depletes B cells, which play a key role in the disease process.<\/p>\n\n\n\n

Global Licensing and Commercialization<\/strong>
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692<\/a>) entered into a licensing agreement with Viela Bio Inc., which was acquired by Horizon Therapeutics plc in 2021 and subsequently by Amgen in 2023. Under the agreement, Hansoh secured development and commercialization rights for Uplizna in Greater China.<\/p>\n\n\n\n

Previous Approvals and Reimbursement<\/strong>
Uplizna has previously been approved in the US, Japan, and the European Union (EU) in 2020, 2021, and 2022, respectively. In China, the drug was approved in March 2022 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and was included in the National Reimbursement Drug List (NRDL) in November 2023.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the…<\/p>\n","protected":false},"author":1,"featured_media":31415,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,363,1182,912,15],"class_list":["post-31412","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-nasdaq-amgn","tag-product-approvals"],"yoast_head":"\nAmgen's Uplizna Approved by FDA for IgG4-Related Disease - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31412\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen's Uplizna Approved by FDA for IgG4-Related Disease\" \/>\n<meta property=\"og:description\" content=\"US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31412\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-08T09:38:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-08T09:38:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amgen’s Uplizna Approved by FDA for IgG4-Related Disease\",\"datePublished\":\"2025-04-08T09:38:56+00:00\",\"dateModified\":\"2025-04-08T09:38:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412\"},\"wordCount\":201,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0818-png.webp\",\"keywords\":[\"Amgen\",\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"NASDAQ: AMGN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31412#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31412\",\"name\":\"Amgen's Uplizna Approved by FDA for IgG4-Related Disease - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0818-png.webp\",\"datePublished\":\"2025-04-08T09:38:56+00:00\",\"dateModified\":\"2025-04-08T09:38:57+00:00\",\"description\":\"US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31412\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0818-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0818-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Amgen's Uplizna Approved by FDA for IgG4-Related Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31412#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen’s Uplizna Approved by FDA for IgG4-Related Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen's Uplizna Approved by FDA for IgG4-Related Disease - Insight, China's Pharmaceutical Industry","description":"US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31412","og_locale":"en_US","og_type":"article","og_title":"Amgen's Uplizna Approved by FDA for IgG4-Related Disease","og_description":"US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).","og_url":"https:\/\/flcube.com\/?p=31412","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-08T09:38:56+00:00","article_modified_time":"2025-04-08T09:38:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31412#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31412"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amgen’s Uplizna Approved by FDA for IgG4-Related Disease","datePublished":"2025-04-08T09:38:56+00:00","dateModified":"2025-04-08T09:38:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31412"},"wordCount":201,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31412#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp","keywords":["Amgen","Hansoh Pharmaceutical","HKG: 3692","NASDAQ: AMGN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31412#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31412","url":"https:\/\/flcube.com\/?p=31412","name":"Amgen's Uplizna Approved by FDA for IgG4-Related Disease - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31412#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31412#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp","datePublished":"2025-04-08T09:38:56+00:00","dateModified":"2025-04-08T09:38:57+00:00","description":"US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon), a CD19 monoclonal antibody (mAb). This approval makes Uplizna the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31412#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31412"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31412#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp","width":1080,"height":608,"caption":"Amgen's Uplizna Approved by FDA for IgG4-Related Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31412#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amgen’s Uplizna Approved by FDA for IgG4-Related Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0818-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31412\/revisions"}],"predecessor-version":[{"id":31416,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31412\/revisions\/31416"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31415"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}